Chokri Ben Lamine: Platelet Subpopulations and Targeted Therapies Across Evidence Levels
Chokri Ben Lamine, Adult Hematology and SCT Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on X:
“Study Stage / Evidence Level – Platelet Subpopulation – Targeted Therapies
Reversible P2Y12 inhibitors (ticagrelor / cangrelor)
- Stage: Phase III (established clinical practice)
- PLATO trial – robust RCT evidence – guideline standard in ACS
- Highest level evidence (Class I recommendation in cardiology guidelines)
GPVI inhibitors (glenzocimab, revacept)
- Stage: Phase II clinical trials
- PCI studies – good safety (decreased bleeding)
- Efficacy signal modest – no reduction in MI yet
- Promising but NOT standard of care
PI3K inhibition (LY294002)
- Stage: Preclinical / experimental
- Mechanistic targeting only
- No clinical application currently
COX-2 targeting / aspirin adjustment
- Stage: Mixed clinical data (small trials / observational)
- No consistent benefit – not guideline recommended
- Conceptual explanation for aspirin resistance
Platelet–immune axis (VEGF / PDGF / αIIbβ3 in cancer)
- Stage: Early clinical / exploratory (e.g., APOLLO study)
- Signal for improved outcomes with ICI combinations
- Hypothesis-generating – not standard oncology practice
S100A8/A9 inhibitors (ABR-215757)
- Stage: Preclinical models
- Demonstrated decreased RP-driven thrombosis
- No human outcome trials yet
SGLT2 inhibitors (indirect platelet modulation)
- Stage: Phase III cardiovascular outcome trials (indirect evidence)
- Proven decreased CV events – platelet benefit inferred
- Not platelet-specific indication but clinically relevant
Summary hierarchy (very high yield)
Phase III / Standard: Ticagrelor / Cangrelor
Phase II / Emerging: GPVI inhibitors
Preclinical / Experimental:
- PI3K inhibitors
- S100A8/A9 inhibitors
Hypothesis / Mixed evidence:
- COX-2 targeting
- Platelet–immune modulation
Clinical pearl
- Only P2Y12 reversible inhibitors currently translate platelet subpopulation biology into routine practice.
- Everything else is precision medicine pipeline (future hematology/cardiology integration).”
Other posts featuring Chokri Ben Lamine on Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS